Nanospheres Encapsulating Anti-leishmanial Drugs for Their Specific Macrophage Targeting, Reduced Toxicity, and Deliberate Intracellular Release

Overview

Journal Vector Borne Zoonotic Dis

Specialties Infectious Diseases
Public Health
Veterinary Medicine

Date 2012 Aug 29

PMID 22925019

Authors

Anil Kumar Shukla

Sanjukta Patra

Vikash Kumar Dubey

Affiliations

Soon will be listed here.

Abstract

The current work focuses on the study of polymeric, biodegradable nanoparticles (NPs) for the encapsulation of doxorubicin and mitomycin C (anti-leishmanial drugs), and their efficient delivery to macrophages, the parasite's home. The biodegradable polymer methoxypoly-(ethylene glycol)-b-poly (lactic acid) (MPEG-PLA) was used to prepare polymeric NPs encapsulating doxorubicin and mitomycin C. The morphology, mean diameter, and surface area of spherical NPs were determined by transmission electron microscopy (TEM), field emission scanning electron microscopy (FESEM), and BET surface area analysis. X-ray diffraction was performed to validate drug encapsulation. An in vitro release profile of the drugs suggested a fairly slow release. These polymeric NPs were efficiently capable of releasing drug inside macrophages at a slower pace than the free drug, which was monitored by epi-fluorescence microscopy. Encapsulation of doxorubicin and mitomycin C into NPs also decreases cellular toxicity in mouse macrophages (J774.1A).

References

Shukla A, Patra S, Dubey V . Evaluation of selected antitumor agents as subversive substrate and potential inhibitor of trypanothione reductase: an alternative approach for chemotherapy of Leishmaniasis. Mol Cell Biochem. 2011; 352(1-2):261-70. DOI: 10.1007/s11010-011-0762-0. View

Desjeux P . Human leishmaniases: epidemiology and public health aspects. World Health Stat Q. 1992; 45(2-3):267-75. View

Brigger I, Dubernet C, Couvreur P . Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002; 54(5):631-51. DOI: 10.1016/s0169-409x(02)00044-3. View

Sett R, Basu N, Ghosh A, Das P . Potential of doxorubicin as an antileishmanial agent. J Parasitol. 1992; 78(2):350-4. View

Lundberg B, Griffiths G, Hansen H . Cellular association and cytotoxicity of anti-CD74-targeted lipid drug-carriers in B lymphoma cells. J Control Release. 2003; 94(1):155-61. DOI: 10.1016/j.jconrel.2003.09.016. View

Yokoyama M, Fukushima S, Uehara R, Okamoto K, Kataoka K, Sakurai Y . Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor. J Control Release. 1998; 50(1-3):79-92. DOI: 10.1016/s0168-3659(97)00115-6. View

Dirix L, Libura M, Libura J, Vermeulen P, de Bruijn E, Van Oosterom A . In vitro toxicity studies with mitomycins and bleomycin on endothelial cells. Anticancer Drugs. 1997; 8(9):859-68. DOI: 10.1097/00001813-199710000-00007. View

Gupta S, Pal A, Vyas S . Drug delivery strategies for therapy of visceral leishmaniasis. Expert Opin Drug Deliv. 2010; 7(3):371-402. DOI: 10.1517/17425240903548232. View

Yi Y, Kim J, Kang H, Oh H, Kim S, Seo M . A polymeric nanoparticle consisting of mPEG-PLA-Toco and PLMA-COONa as a drug carrier: improvements in cellular uptake and biodistribution. Pharm Res. 2005; 22(2):200-8. DOI: 10.1007/s11095-004-1187-1. View

10.

Gref R, Domb A, Quellec P, Blunk T, Muller R, Verbavatz J . The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev. 2014; 16(2-3):215-233. PMC: 4144462. DOI: 10.1016/0169-409X(95)00026-4. View

11.

Desai M, Labhasetwar V, Walter E, Levy R, Amidon G . The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res. 1998; 14(11):1568-73. DOI: 10.1023/a:1012126301290. View

12.

Tardi P, Boman N, Cullis P . Liposomal doxorubicin. J Drug Target. 1996; 4(3):129-40. DOI: 10.3109/10611869609015970. View

13.

Righetti P . Charge-state and charge-continuum models in electrophoresis and isoelectric focusing of genetic variants. J Chromatogr. 1979; 173(1):1-5. DOI: 10.1016/s0021-9673(01)80440-4. View

14.

Kedzierski L, Zhu Y, Handman E . Leishmania vaccines: progress and problems. Parasitology. 2007; 133 Suppl:S87-112. DOI: 10.1017/S0031182006001831. View

15.

Panyam J, Labhasetwar V . Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003; 55(3):329-47. DOI: 10.1016/s0169-409x(02)00228-4. View

16.

Service R . Materials and biology. Nanotechnology takes aim at cancer. Science. 2005; 310(5751):1132-4. DOI: 10.1126/science.310.5751.1132. View

17.

Jones M, Leroux J . Polymeric micelles - a new generation of colloidal drug carriers. Eur J Pharm Biopharm. 1999; 48(2):101-11. DOI: 10.1016/s0939-6411(99)00039-9. View

18.

Zheng X, Kan B, Gou M, Fu S, Zhang J, Men K . Preparation of MPEG-PLA nanoparticle for honokiol delivery in vitro. Int J Pharm. 2009; 386(1-2):262-7. DOI: 10.1016/j.ijpharm.2009.11.014. View

19.

Gordon S . The macrophage. Bioessays. 1995; 17(11):977-86. DOI: 10.1002/bies.950171111. View

20.

Shukla A, Singh B, Patra S, Dubey V . Rational approaches for drug designing against leishmaniasis. Appl Biochem Biotechnol. 2009; 160(8):2208-18. DOI: 10.1007/s12010-009-8764-z. View